FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.

2.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

3.

Cancer detection recovered following pandemic disruptions

4.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

5.

Research identifies nearly 200 potential breast carcinogens in food packaging materials


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot